Evidence map›Paper›PMID 38583096›Full record

ReviewBiochemical genetics2025

Moringa oleifera and Its Biochemical Compounds: Potential Multi-targeted Therapeutic Agents Against COVID-19 and Associated Cancer Progression.

Ali Yousefi Rad, Ali Asghar Rastegari, Kahin Shahanipour, Ramesh Monajemi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Biochemical genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ali Yousefi RadDepartment of Biochemistry, Falavarjan Branch, Islamic Azad University, Esfahan, Iran.
Ali Asghar RastegariDepartment of Molecular and Cell Biochemistry, Falavarjan Branch, Islamic Azad University, Esfahan, Iran. aarastegari@gmail.com.
Kahin ShahanipourDepartment of Biochemistry, Falavarjan Branch, Islamic Azad University, Esfahan, Iran.
Ramesh MonajemiDepartment of Biology, Falavarjan Branch, Islamic Azad University, Esfahan, Iran.
Islamic Azad University of Falavarjan · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Coronavirus disease-2019 (COVID-19) pandemic is a global concern, with updated pharmacological therapeutic strategies needed. Cancer patients have been found to be more susceptible to severe COVID-19 and death, and COVID-19 can also lead to cancer progression. Traditional medicinal plants have long been used as anti-infection and anti-inflammatory agents, and Moringa oleifera (M. oleifera) is one such plant containing natural products such as kaempferol, quercetin, and hesperetin, which can reduce inflammatory responses and complications associated with viral infections and multiple cancers. This review article explores the cellular and molecular mechanisms of action of M. oleifera as an anti-COVID-19 and anti-inflammatory agent, and its potential role in reducing the risk of cancer progression in cancer patients with COVID-19. The article discusses the ability of M. oleifera to modulate NF-κB, MAPK, mTOR, NLRP3 inflammasome, and other inflammatory pathways, as well as the polyphenols and flavonoids like quercetin and kaempferol, that contribute to its anti-inflammatory properties. Overall, this review highlights the potential therapeutic benefits of M. oleifera in addressing COVID-19 and associated cancer progression. However, further investigations are necessary to fully understand the cellular and molecular mechanisms of action of M. oleifera and its natural products as anti-inflammatory, anti-COVID-19, and anti-cancer strategies.

Indexed as

Anti-Inflammatory AgentsCOVID-19 Drug TreatmentMoringa oleiferaNeoplasmsPlant ExtractsCOVID-19Disease ProgressionHumansPandemicsSARS-CoV-2Anti-Inflammatory AgentsPlant ExtractsCancer progressionCOVID-19InflammationMoringa oleiferaSARS-CoV-2

Identifiers

PMID38583096
OpenAlexW4394062404

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.